Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma – an auto-commentary on clinical potential and future development

Yunching Chen; Dan G. Duda

doi:10.1080/2162402X.2015.1029703

Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma – an auto-commentary on clinical potential and future development

Yunching Chen, Dan G. Duda

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Immunotherapy has shown great promise to transform solid cancer treatment. The challenge is to optimally incorporate novel immunotherapeutics, such as immune checkpoint blockers, with standard therapies. This is well exemplified by multimodal therapies recently developed for liver cancer in which immunomodulation using CXCR4 inhibition prevented immunosuppression and enhanced sorafenib and anti-PD-1 therapeutic outcome.

Original language	English (US)
Journal	OncoImmunology
Volume	4
Issue number	10
DOIs	https://doi.org/10.1080/2162402X.2015.1029703
State	Published - Oct 3 2015

Keywords

combination therapy
CXCR4 hepatocellular carcinoma
immune checkpoint blockade
immunosuppression
PD-1

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.1080/2162402X.2015.1029703

Cite this

@article{b8639c81c6e542669b8ab381956ddbec,

title = "Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma – an auto-commentary on clinical potential and future development",

abstract = "Immunotherapy has shown great promise to transform solid cancer treatment. The challenge is to optimally incorporate novel immunotherapeutics, such as immune checkpoint blockers, with standard therapies. This is well exemplified by multimodal therapies recently developed for liver cancer in which immunomodulation using CXCR4 inhibition prevented immunosuppression and enhanced sorafenib and anti-PD-1 therapeutic outcome.",

keywords = "combination therapy, CXCR4 hepatocellular carcinoma, immune checkpoint blockade, immunosuppression, PD-1",

author = "Yunching Chen and Duda, \{Dan G.\}",

note = "Publisher Copyright: {\textcopyright} 2015 Taylor \& Francis Group, LLC.",

year = "2015",

month = oct,

day = "3",

doi = "10.1080/2162402X.2015.1029703",

language = "English (US)",

volume = "4",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Taylor and Francis Ltd.",

number = "10",

}

TY - JOUR

T1 - Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma – an auto-commentary on clinical potential and future development

AU - Chen, Yunching

AU - Duda, Dan G.

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Immunotherapy has shown great promise to transform solid cancer treatment. The challenge is to optimally incorporate novel immunotherapeutics, such as immune checkpoint blockers, with standard therapies. This is well exemplified by multimodal therapies recently developed for liver cancer in which immunomodulation using CXCR4 inhibition prevented immunosuppression and enhanced sorafenib and anti-PD-1 therapeutic outcome.

AB - Immunotherapy has shown great promise to transform solid cancer treatment. The challenge is to optimally incorporate novel immunotherapeutics, such as immune checkpoint blockers, with standard therapies. This is well exemplified by multimodal therapies recently developed for liver cancer in which immunomodulation using CXCR4 inhibition prevented immunosuppression and enhanced sorafenib and anti-PD-1 therapeutic outcome.

KW - combination therapy

KW - CXCR4 hepatocellular carcinoma

KW - immune checkpoint blockade

KW - immunosuppression

KW - PD-1

UR - https://www.scopus.com/pages/publications/84940706564

UR - https://www.scopus.com/inward/citedby.url?scp=84940706564&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1029703

DO - 10.1080/2162402X.2015.1029703

M3 - Article

AN - SCOPUS:84940706564

SN - 2162-4011

VL - 4

JO - OncoImmunology

JF - OncoImmunology

IS - 10

ER -

Targeting immunosuppression after standard sorafenib treatment to facilitate immune checkpoint blockade in hepatocellular carcinoma – an auto-commentary on clinical potential and future development

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this